MedPath

Mussels, Inflammation and Rheumatoid Arthritis (MIRA)

Not Applicable
Completed
Conditions
Rheumatoid Arthritis
Interventions
Other: Blue mussel diet
Other: Meat/Control diet
Registration Number
NCT02522052
Lead Sponsor
Göteborg University
Brief Summary

Rheumatoid arthritis (RA) is a chronic disease that affects \~1% of the population. A large proportion of patients with established disease have persistent high disease activity in spite of existing effective pharmacological treatment. Improved treatment is thus urgently needed, including alternative treatments in addition to optimal pharmacological therapy. The main purpose of this study is to investigate if a high intake of blue mussel (Mytilus Edulis) could decrease inflammation and disease activity in patients with established RA. A secondary goal is to identify novel biomarkers for blue mussel intake and metabolic responses to this diet, using a metabolomics approach with high sensitivity and specificity. A third goal is to look at genetic polymorphisms in relation to long chain polyunsaturated fatty acids (LCPUFA) and inflammatory markers.

Detailed Description

Rheumatoid arthritis (RA) is a chronic disease that affects \~1% of the population. A large proportion of patients with established disease have persistent high disease activity in spite of existing effective pharmacological treatment. Improved treatment is thus urgently needed, including alternative treatments in addition to optimal pharmacological therapy. The main purpose of this study is to investigate if a high intake of blue mussel (Mytilus Edulis) could decrease inflammation and disease activity in patients with established RA. A secondary goal is to identify novel biomarkers for blue mussel intake and metabolic responses to this diet, using a metabolomics approach with high sensitivity and specificity. A third goal is to look at genetic polymorphisms in relation to LCPUFA and inflammatory markers.

Diet and lifestyle are associated with chronic diseases such as cardiovascular diseases, cancer and diabetes. Here, evidence based dietary treatment guidelines are available. In contrast, for inflammatory diseases such as RA no dietary guidelines exist, reflecting the ambiguous evidence base. Many dietary components are related to the human immune system or to inflammation. Some are co-factors in immune- or inflammatory response, such as zinc. Others are antioxidants, eg selenium, vitamins E and C. RA has been associated with low serum concentrations of zinc, selenium, vitamins D and B6 although some of this may reflect inflammatory response. Dietary effects on RA symptoms have been reported for long chain fatty acids from fish and probiotics have shown to improve function in RA patients. As prebiotics reduce inflammation in other conditions, it may have positive effects also on RA. Most research on antioxidants has focused on single nutrients but a few dietary trials also have been conducted with mixed results. In sum, high-quality studies evaluating the effect of a combination of food items with indicative effects on RA are needed.

Blue mussels are rich in vitamins (B2 and B12) and minerals (iron, selenium and zinc) and contain the LCPUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
23
Inclusion Criteria
  • BMI 18-40 kg/m2,
  • disease duration >2 years,
  • DAS28 >3.0
Exclusion Criteria
  • other Life-threatening disease,
  • pregnant,
  • lactating,
  • food intolerant or allergic to food included in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Blue mussel dietBlue mussel diet5 meals a week including blue mussels
Meat/control dietMeat/Control diet5 meals a week including meat
Primary Outcome Measures
NameTimeMethod
difference between disease activity score 28 (DAS28) after the dietsafter 11 week intervention

Measured clinically

Secondary Outcome Measures
NameTimeMethod
difference in inflammatory markers/cytokines (IL-1beta, IL-6, Tumor Necrosis Factor-alfa, IL-10) after the dietsafter 11 week intervention

measured in blood

Difference in Quality of life and health by SF36, EQ5D och HAQ after the dietsafter 11 week intervention

Measured by validated instruments (SF36, EQ5D och HAQ)

Differences and changes in metabolites after the two dietsafter 11 week intervention

Metabolomics Nuclear magnetic resonance (NMR) analysis of serum and urin samples.

Trial Locations

Locations (1)

Sahlgrenska University Hospital

🇸🇪

Göteborg, Not In US/Canada, Sweden

© Copyright 2025. All Rights Reserved by MedPath